top of page
Professor John Campbell PhD FRSB shares insights into how treatment resistance in solid tumours can be overcome
We spoke to Professor John Campbell PhD FRSB, a member of our Scientific Advisory Board, to discuss a key question in oncology: How can treatment resistance in solid tumours be overcome?
Apr 24, 2025
Dr. Mark A. Exley shares what excites him most about joining LIfT as Chief Scientific Officer and the potential of LIfT’s technology
In this video, Dr. Mark A. Exley shares his background in biotech, what makes our neutrophil-based approach to cancer therapy so...
Apr 8, 2025
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer
Mark brings 30 years of experience in R&D spanning discovery to late-stage clinical development London, 7 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and world leader in neutrophil immuno-therapies, today announces the appointment of Mark A. Exley, PhD as Chief Scientific Officer (CSO), effective 7 April. The appointment of a CSO with extensive clinical expertise comes at a pivotal time for LIfT, as the Company prepares for clinical tr
Apr 7, 2025
bottom of page